

To the OMX  
Announcement No. 44-07 / Copenhagen, 17 December 2007

**TopoTarget A/S**  
Symbion  
Fruebjergvej 3  
DK 2100 Copenhagen Ø  
Denmark  
Tel: +45 39 17 83 92  
Fax: +45 39 17 94 92  
CVR-nr: 25695771

[www.topotarget.com](http://www.topotarget.com)

### **AntiAnthra ApS transferring shares to Prospero Limited**

- Notification pursuant to section 28a of the Danish Securities Trading Act -

**Copenhagen, Denmark – 17 December 2007** – Pursuant to section 28a of the Danish Securities Trading Act, TopoTarget (OMX: TOPO) hereby reports that on 16 December 2007, one of the owners of AntiAnthra ApS transferred, a total of 205,000 TopoTarget shares (ISIN DK0060086072) from AntiAnthra ApS to another company; Prospero Limited.

AntiAnthra ApS is a company which is a related party to Peter Buhl Jensen, the Chief Executive Officer of TopoTarget A/S, and to Maxwell Sehested, the Chief Scientific Officer of TopoTarget A/S.

The reported transaction consisted of a transfer from AntiAnthra, to a third shareholder of AntiAnthra ApS namely Prospero Limited. In connection with the transfer, the said shareholder will cease to be a shareholder of AntiAnthra ApS.

Despite the fact that the transaction is legally comprised by Section 28a of the Danish Securities Trading Act, it is noted that Peter Buhl Jensen and Maxwell Sehested directly and indirectly own the same number of shares in TopoTarget A/S as before the transaction. The market value of the transferred shares totals DKK 4,202,500.

As the transaction was a transfer only it is not applicable to state a relevant market.

**TopoTarget A/S**



## AntiAntra ApS transferring shares to Prospero Limited

For further information, please contact:

Dr. Peter Buhl Jensen	Telephone	+45 39 17 83 41
Chief Executive Officer	Mobile	+45 21 60 89 22

### Background information

#### About TopoTarget

TopoTarget (OMX: TOPO) is a biotech company, headquartered in Denmark and with subsidiaries in the US, Switzerland, Germany and the UK, dedicated to finding "Answers for Cancer" and developing improved cancer therapies. TopoTarget is founded and run by clinical cancer specialists and combines years of hands-on clinical experience with in-depth understanding of the molecular mechanisms of cancer. Focus lies on highly predictive cancer models and key cancer targets (including HDACi, NAD+, mTOR, FasLigand and topoisomerase II inhibitors) and a strong development foundation has been built. TopoTarget has a broad portfolio of small molecule pre-clinical drug candidates and nine drugs (both small molecules and protein based) are in clinical development, including both novel anti-cancer therapeutics and new cancer indications for existing drugs. Savene™/Totect™ was approved by EMEA in 2006 and the FDA in 2007 and is TopoTarget's first product on the market. For more information, please refer to [www.topotarget.com](http://www.topotarget.com).

#### TopoTarget Safe Harbour Statement

This announcement may contain forward-looking statements, including statements about our expectations of the progression of our preclinical and clinical pipeline including the timing for commencement and completion of clinical trials and with respect to cash burn guidance. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. TopoTarget cautions investors that there can be no assurance that actual results or business conditions will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors, including, but not limited to, the following: The risk that any one or more of the drug development programs of TopoTarget will not proceed as planned for technical, scientific or commercial reasons or due to patient enrolment issues or based on new information from non-clinical or clinical studies or from other sources; the success of competing products and technologies; technological uncertainty and product development risks; uncertainty of additional funding; TopoTarget's history of incurring losses and the uncertainty of achieving profitability; TopoTarget's stage of development as a biopharmaceutical company; government regulation; patent infringement claims against TopoTarget's products, processes and technologies; the ability to protect TopoTarget's patents and proprietary rights; uncertainties relating to commercialization rights; and product liability expo-sure; We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by law.

